From the Research
There is no evidence that maternal use of Skyrizi (risankizumab) causes bloody stools in breastfed infants. Skyrizi is a monoclonal antibody used to treat psoriasis and other inflammatory conditions, and like other large protein molecules, it is expected to be present in breast milk in very small amounts and poorly absorbed by the infant's digestive system. The molecular weight of risankizumab (approximately 149 kDa) makes it unlikely to significantly transfer into breast milk or be absorbed intact by the infant's gastrointestinal tract. While limited data exists specifically on Skyrizi during breastfeeding, similar biologics have not shown significant adverse effects in breastfed infants 1. However, if a breastfed infant develops bloody stools while the mother is taking Skyrizi, this should be reported to a healthcare provider immediately as it could be due to other causes that require medical attention. The decision to use Skyrizi while breastfeeding should be made in consultation with healthcare providers, weighing the benefits of the medication for the mother against potential risks to the infant. Some key points to consider when making this decision include:
- The potential benefits of Skyrizi for the mother's condition, such as improved symptoms and quality of life
- The potential risks of Skyrizi to the breastfed infant, although these appear to be low based on current evidence
- The importance of monitoring the infant for any signs of adverse effects, such as bloody stools, and seeking medical attention if necessary
- The need for ongoing consultation with healthcare providers to ensure the best possible outcomes for both the mother and the infant. It's also worth noting that the most recent and highest quality study on this topic is from 2024 1, which provides the most up-to-date information on the safety and efficacy of Skyrizi. Overall, the available evidence suggests that Skyrizi is unlikely to cause significant harm to breastfed infants, but as with any medication, it's essential to carefully weigh the potential benefits and risks and to monitor the infant for any signs of adverse effects.